Karyopharm to Present Selinexor Data at Notable Medical Conference
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), known for its innovative cancer therapies, is excited to announce that it will be showcasing important new data on its drug selinexor at the upcoming 66th American Society of Hematology (ASH) Annual Meeting and Exposition. This event serves as a significant platform for medical advancements and will gather leading experts in hematology.
Presentations of Key Findings
During the ASH 2024 meeting, the Karyopharm team will present findings that highlight the effectiveness of selinexor, particularly in the treatment of multiple myeloma and myelofibrosis. Dr. Reshma Rangwala, Chief Medical Officer at Karyopharm, expressed enthusiasm about these presentations, stating, "We are thrilled to share our findings on selinexor at this year’s annual meeting, which emphasize the hard work of our team and collaborators towards advancing treatment in these critical areas."
Abstracts Overview
Multiple abstracts concerning selinexor have been selected for presentation at the conference. Notably, one key abstract discusses the efficacy and safety of selinexor combined with other drugs, specifically pomalidomide and dexamethasone, in patients with relapsed or refractory multiple myeloma. This presentation is scheduled for December 7, from 5:30 PM to 7:30 PM PST.
Furthermore, another significant abstract that delves into myelofibrosis is titled "Selinexor Depletes Ruxolitinib Refractory Myelofibrosis Hematopoietic Stem Cells By Inducing Apoptosis and Blunting the Pro-Inflammatory Milieu," which will be presented on the same day and time.
Partner Presentations
A selected presentation by Antengene will also contribute to the ongoing discussions on selinexor, featuring new data on its therapeutic uses in treating hematological malignancies.
Understanding Selinexor: XPOVIO®
XPOVIO (selinexor) is Karyopharm's cornerstone product and stands out as a first-in-class oral exportin 1 (XPO1) inhibitor. It works by blocking the protein responsible for exporting key tumor suppressor proteins out of the cell, thereby helping to combat cancer growth. Currently, XPOVIO is approved for several indications, including use in multiple myeloma after a minimum of one prior treatment and for specific cases of diffuse large B-cell lymphoma.
The drug is gaining traction globally, with approvals in regions outside the U.S., such as Europe and China. As Karyopharm continuously works to expand its clinical portfolio, selinexor is concurrently undergoing investigation in various late-stage trials for multiple cancer types, further emphasizing the company's commitment to addressing high unmet medical needs.
Important Safety Information
Before using XPOVIO, healthcare professionals advise patients about certain risks associated with the treatment. Common adverse effects can include fatigue, nausea, and gastrointestinal issues, which may arise from its usage in conjunction with other therapies. Monitoring and supportive care are essential throughout treatment to manage any potential side effects effectively.
About Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. is a commercial-stage biopharmaceutical company that is dedicated to developing innovative therapies for patients with cancer. With a focus on addressing the core challenges associated with tumor progression, Karyopharm's pipeline is designed to tackle several high-need cancer indications, including multiple myeloma and myelofibrosis. Their commitment is driven by the strength and determination of patients battling cancer.
Frequently Asked Questions
What will Karyopharm present at the ASH meeting?
Karyopharm will present important new data on its drug selinexor, focusing on its efficacy in treating multiple myeloma and myelofibrosis.
When is the ASH meeting?
The 66th American Society of Hematology Annual Meeting will take place from December 7-10, 2024.
What is XPOVIO?
XPOVIO is an oral cancer therapy developed by Karyopharm, specifically designed to inhibit XPO1, which plays a role in tumor growth.
What are the common side effects of selinexor?
Patients may experience side effects like fatigue, nausea, and gastrointestinal issues, which require monitoring throughout treatment.
How does Karyopharm support patient needs?
Karyopharm is committed to improving cancer treatment through continuous research and development, focusing on therapies that meet the needs of patients with high unmet medical needs.
